CN115300458A - 一种无糖地氯雷他定口服溶液及其制备方法 - Google Patents
一种无糖地氯雷他定口服溶液及其制备方法 Download PDFInfo
- Publication number
- CN115300458A CN115300458A CN202210943363.3A CN202210943363A CN115300458A CN 115300458 A CN115300458 A CN 115300458A CN 202210943363 A CN202210943363 A CN 202210943363A CN 115300458 A CN115300458 A CN 115300458A
- Authority
- CN
- China
- Prior art keywords
- desloratadine
- sugar
- free
- oral solution
- percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940113256 desloratadine oral solution Drugs 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 21
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 21
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960001271 desloratadine Drugs 0.000 claims abstract description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 22
- 239000008213 purified water Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 13
- 239000004376 Sucralose Substances 0.000 claims description 13
- 239000000600 sorbitol Substances 0.000 claims description 13
- 235000010356 sorbitol Nutrition 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 13
- 235000019408 sucralose Nutrition 0.000 claims description 13
- 241000220223 Fragaria Species 0.000 claims description 12
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 12
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 12
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 10
- 239000001509 sodium citrate Substances 0.000 claims description 10
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 10
- 235000011083 sodium citrates Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 2
- 235000019640 taste Nutrition 0.000 abstract description 15
- 235000019658 bitter taste Nutrition 0.000 abstract description 5
- 229940100688 oral solution Drugs 0.000 abstract description 3
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 238000013112 stability test Methods 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 239000008347 soybean phospholipid Substances 0.000 description 3
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013210 evaluation model Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- -1 loratadine Chemical compound 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种无糖地氯雷他定口服溶液及制备方法。本发明无糖地氯雷他定口服溶液中添加了1.5％‑2.5％的大豆卵磷脂来掩盖地氯雷他定的苦味，已达到使用少量的甜味剂就可以提高制剂口感的目的。本发明的地氯雷他定口服溶液，制备方法简单，口味良好。通过稳定性试验，该口服溶液质量稳定，适合儿童服用。
Description
技术领域
本发明属于药物制剂领域，具体涉及一种无糖地氯雷他定口服溶液及其制备方法
背景技术
地氯雷他定为第二代抗组胺药氯雷他定主要活性代谢产物，为长效三环类第三代抗组胺药，可用于治疗过敏性鼻炎和过敏性鼻炎哮喘，并且有效缓解过敏性鼻炎症状，如打喷嚏、流涕、鼻痒、鼻粘膜充血\鼻塞、眼痒、流泪、眼结膜充血和上腭痒，作用可持续24小时。
仿制药参比制剂目录(第二十二批)公布欧盟上市的Merck Sharp&Dohme B.V生产的地氯雷他定口服溶液为参比制剂，目前国内上市的地氯雷他定剂型为片剂、干混悬剂、糖浆剂。对于儿童来说，地氯雷他定较为方便的服用剂型为口服溶液、干混悬剂或糖浆剂。而为了掩盖药物的苦味，往往制剂中会加入大量蔗糖，而过多摄入蔗糖会导致儿童蛀牙及高血糖，甚至引发糖尿病。
为使儿童更为健康的服用地氯雷他定口服溶液，特提出本发明。
发明内容
本发明的目的是提供一种无糖地氯雷他定口服溶液及制备方法。
本发明所提供的无糖地氯雷他定口服溶液，含有地氯雷他定、质量体积含量为1.5-2.5％的大豆卵磷脂、丙二醇、无水枸橼酸、枸橼酸钠、山梨醇、三氯蔗糖、草莓香精、纯化水。
进一步的，所述无糖地氯雷他定口服溶液，由下述质量体积百分含量(g/100ml)的原料组成：地氯雷他定0.05％、大豆卵磷脂1.5-2.5％、丙二醇8％-12％、无水枸橼酸0.033％、枸橼酸钠0.08％、山梨醇1.65％-1.69％、三氯蔗糖0.04％-0.06％、草莓香精0.01％-0.03％，余量为纯化水。
更进一步的，所述无糖地氯雷他定口服溶液，由下述质量体积百分含量(g/100ml)的原料组成：地氯雷他定0.05％、大豆卵磷脂1.5-2.5％、丙二醇10％、无水枸橼酸0.033％、枸橼酸钠0.08％、山梨醇1.67％、三氯蔗糖0.05％、草莓香精0.02％、余量为纯化水。
本发明还提供了上述无糖地氯雷他定口服溶液的制备方法，包含如下步骤：
(1)取丙二醇加热至30-50℃，加入大豆卵磷脂，溶解后加入原料药地氯雷他定，搅拌至溶解；
(2)加入60％配液量纯化水，搅拌均匀；
(3)依次加入无水枸橼酸、枸橼酸钠、山梨醇、三氯蔗糖、草莓香精，搅拌至溶解；
(4)加纯化水至全量，即得。
与现有技术相比，本发明具有如下有益效果：
该地氯雷他定口服溶液处方中加入大豆卵磷脂可较好掩饰苦味，再加入少量山梨醇及矫味剂三氯蔗糖和香精以提高口感；该制备方法过程简便、易操作，省时节能，适合工业化大生产，制备得到的口服溶液质量稳定、口味较好、更适合儿童服用。
具体实施方式
下面结合具体实施例对本发明作进一步阐述，但本发明并不限于以下实施例。所述方法如无特别说明均为常规方法。所述原材料如无特别说明均能从公开商业途径获得。
实施例1-5：
实施例1-5、对比例1无糖地氯雷他定口服溶液的处方组成如表1。
表1无糖地氯雷他定口服溶液的处方组成
| 实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | 对比例1 | |
| 地氯雷他定 | 0.05g | 0.05g | 0.05g | 0.05g | 0.05g | 0.05g |
| 大豆卵磷脂 | 1.0g | 1.5g | 2.0g | 2.5g | 3.0g | / |
| 丙二醇 | 10g | 12g | 10g | 8g | 10g | 10g |
| 无水枸橼酸 | 0.033g | 0.033g | 0.033g | 0.033g | 0.033g | 0.033g |
| 枸橼酸钠 | 0.080g | 0.080g | 0.080g | 0.080g | 0.080g | 0.080g |
| 山梨醇 | 1.69g | 1.69g | 1.67g | 1.65g | 1.67g | 1.67g |
| 三氯蔗糖 | 0.05g | 0.04g | 0.05g | 0.06g | 0.06g | 0.05g |
| 草莓香精 | 0.02g | 0.01g | 0.02g | 0.03g | 0.03g | 0.02g |
| 纯化水加至 | 100ml | 100ml | 100ml | 100ml | 100ml | 100ml |
实施例1-5无糖地氯雷他定口服溶液的制备工艺相同，具体为：
(1)处方量丙二醇加热至30-50℃，加入大豆卵磷脂，溶解后加入原料药，搅拌至溶解；
(2)加入60％配液量纯化水，搅拌均匀；
(3)依次加入无水枸橼酸、枸橼酸钠、山梨醇、三氯蔗糖、草莓香精，搅拌至溶解；
(4)加纯化水至全量。
对比例1无糖地氯雷他定口服溶液的制备工艺同实施例1-5，区别在于步骤(1)中不加入大豆卵磷脂。
实施例1-5、对比例1无糖地氯雷他定口服溶液产品质量评价
1、模糊数学评价法进行口感评价
由20名评价员(身体健康，男7名，女13名，年龄23-45岁)对实施例1-5及对比例1制备的无糖地氯雷他定口服溶液的口感进行评价，根据口感调查表对所品尝的药液进行打分，汇总统计结果见下表。选择苦味、口腔余味、粘稠度、总体口感作为评价指标，权重分别为0.3、0.15、0.15、0.4；以很好(5分)、好(4分)、中(3分)、差(2分)、很差(1分)作为口感评价等级，即评语集。根据口感评定统计结果，建立矩阵，采用模糊数学评价模型进行分析。
表2口感评定结果
结果处理：
将综合评价的结果用Y表示。模糊关系综合评价集Y＝H×M，其中权重集为：H＝(0.3、0.15、0.15、0.4)，模糊矩阵为M。将表2中苦味、口腔余味、粘稠度、总体口感评价结果初一总评价人数，可得各试验的模糊矩阵。如
同理
根据模糊变换原理，采用普通矩阵乘法对各类因素的综合结果进行计算，即Y＝H×M。
如
同理Y2＝(0.15 0.5125 0.465 0.0225 0)，Y3＝(0.1675 0.645 0.2075 0 0)，Y4＝(0.14 0.735 0.1175 0.0075 0)，Y5＝(0.08 0.4075 0.3175 0.1275 0)，Y对1＝(0 0.0150.2025 0.4025 0)
将各评语集对应的分值与模糊综合评价的结果相乘、相加，得到各实施例的综合评分结果。如Q1＝0×5+0.12×4+0.08×3+0.605×2+0.195×1＝2.125，同理Q2＝4.24，Q3＝4.04，Q4＝4.0075，Q5＝3.2375，Q对1＝1.4725。
由各实施例综合评分的结果可知，综合排序为：实施例2＞3＞4＞5＞1＞对比例1，其中实施例2、3、4得分大于4分，为“好”，说明评价组对这三个实施例的口感评价认可度高，为无糖地氯雷他定口服溶液的最优处方，即加入1.5-2.5％的大豆卵磷脂的无糖地氯雷他定口服溶液的口味较好。
2、稳定性考察
将未加大豆卵磷脂的对比例1与实施例2-4进行质量对比及稳定性考察，结果如下：
表3地氯雷他定口服溶液0天检测结果
结论：本发明处方制备的含有大豆卵磷脂的无糖地氯雷他定口服溶液0天杂质水平同不加大豆卵磷脂的无糖地氯雷他定口服溶液相当。
表4地氯雷他定口服溶液光照(照度4500lx±500lx)30天试验结果
表5地氯雷他定口服溶液高温(60℃±2℃)30天试验结果
结论：影响因素试验结果表明，实施例2-4的含有大豆卵磷脂的无糖地氯雷他定口服溶液及参比制剂在光照、高温条件下，性状、pH值、有关物质均未发生显著变化，稳定性良好。且与未加入大豆卵磷脂的样品相比无明显差别。
表6地氯雷他定口服溶液长期稳定性(25℃，60％RH)12个月试验结果
结论：实施例2-4的含有大豆卵磷脂无糖地氯雷他定口服溶液及参比制剂，性状、pH值、有关物质均未发生显著变化，产品质量稳定。且与未加入大豆卵磷脂的样品相比，未发生显著变化。
实施例6-8添加大豆卵磷脂含量均匀性考察
实施例6-8无糖地氯雷他定口服溶液的处方组成如表7。
表7无糖地氯雷他定口服溶液的处方组成
| 实施例 | 6 | 7 | 8 |
| 地氯雷他定 | 1.00g | 1.00g | 1.00g |
| 大豆卵磷脂 | 30g | 40g | 50g |
| 丙二醇 | 200g | 200g | 200g |
| 无水枸橼酸 | 0.66g | 0.66g | 0.66g |
| 枸橼酸钠 | 1.60g | 1.60g | 1.60g |
| 山梨醇 | 33.4g | 33.4g | 33.4g |
| 三氯蔗糖 | 1.0g | 1.0g | 1.0g |
| 草莓香精 | 0.4g | 0.4g | 0.4g |
| 纯化水加至 | 2000ml | 2000ml | 2000ml |
实施例6-8无糖地氯雷他定口服溶液的制备工艺相同，具体为：
(1)处方量丙二醇加热至30-50℃，加入大豆卵磷脂，溶解后加入原料药，搅拌至溶解；
(2)加入60％配液量纯化水，搅拌均匀；
(3)依次加入无水枸橼酸、枸橼酸钠、山梨醇、三氯蔗糖、草莓香精，搅拌至溶解；
(4)加纯化水至全量。
(5)全量后，分别在搅拌5、10分钟时，在药液的上层、中层、下层取样对含量均匀性进行研究。
表8含量均匀性考察结果
结论：采用本发明处方及方法制备的无糖地氯雷他定口服溶液，全量后搅拌5-10分钟即可使含量均匀。
采用本发明处方及方法制备的无糖地氯雷他定口服溶液，质量稳定、口味较好、更适合儿童服用。
Claims (4)
1.一种无糖地氯雷他定口服溶液，含有地氯雷他定丙二醇、无水枸橼酸、枸橼酸钠、山梨醇、三氯蔗糖、草莓香精、纯化水；其特征在于：所述无糖地氯雷他定口服溶液含有质量体积含量为1.5-2.5％的大豆卵磷脂。
2.根据权利要求1所述的无糖地氯雷他定口服溶液，其特征在于：所述无糖地氯雷他定口服溶液，由下述质量体积百分含量的原料组成：地氯雷他定0.05％、大豆卵磷脂1.5-2.5％、丙二醇8％-12％、无水枸橼酸0.030％-0.036％、枸橼酸钠0.07％-0.09％、山梨醇1.65％-1.69％、三氯蔗糖0.04％-0.06％、草莓香精0.01％-0.03％，余量为纯化水。
3.根据权利要求1或2所述的无糖地氯雷他定口服溶液，其特征在于：所述无糖地氯雷他定口服溶液，由下述质量体积百分含量的原料组成：地氯雷他定0.05％、大豆卵磷脂1.5-2.5％、丙二醇10％、无水枸橼酸0.033％、枸橼酸钠0.08％、山梨醇1.67％、三氯蔗糖0.05％、草莓香精0.02％、余量为纯化水。
4.权利要求1-3中任一项所述无糖地氯雷他定口服溶液的制备方法，包含如下步骤：
(1)取丙二醇加热至30-50℃，加入大豆卵磷脂，溶解后加入原料药地氯雷他定，搅拌至溶解；
(2)加入60％配液量纯化水，搅拌均匀；
(3)依次加入无水枸橼酸、枸橼酸钠、山梨醇、三氯蔗糖、草莓香精，搅拌至溶解；
(4)加纯化水至全量，即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210943363.3A CN115300458B (zh) | 2022-08-08 | 2022-08-08 | 一种无糖地氯雷他定口服溶液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210943363.3A CN115300458B (zh) | 2022-08-08 | 2022-08-08 | 一种无糖地氯雷他定口服溶液及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115300458A true CN115300458A (zh) | 2022-11-08 |
| CN115300458B CN115300458B (zh) | 2023-11-07 |
Family
ID=83861032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210943363.3A Active CN115300458B (zh) | 2022-08-08 | 2022-08-08 | 一种无糖地氯雷他定口服溶液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115300458B (zh) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001000178A1 (fr) * | 1999-06-29 | 2001-01-04 | Takeda Chemical Industries, Ltd. | Comprimes se desintegrant rapidement dans la bouche |
| WO2005016310A1 (en) * | 2003-08-08 | 2005-02-24 | Elan Pharma International Ltd. | Novel metaxalone compositions |
| US20060140989A1 (en) * | 2004-12-22 | 2006-06-29 | Schering Corporation | Pharmaceutical formulations |
| CN104027566A (zh) * | 2014-06-06 | 2014-09-10 | 浙江天冉药物研究有限公司 | 健儿消食口服液及其制备工艺 |
| CN104758919A (zh) * | 2015-03-30 | 2015-07-08 | 锦州奥鸿药业有限责任公司 | 一种小牛血清去蛋白注射液及其制备方法 |
| CN107349351A (zh) * | 2017-08-07 | 2017-11-17 | 陕西必康制药集团控股有限公司 | 一种健儿消食口服液及其制备方法 |
| CN113730336A (zh) * | 2021-09-27 | 2021-12-03 | 浙江核力欣健药业有限公司 | 一种氯雷他定糖浆剂及其制备方法 |
| CN114588106A (zh) * | 2022-03-21 | 2022-06-07 | 哈尔滨圣泰生物制药有限公司 | 一种地氯雷他定口服溶液制剂及其制备生产工艺 |
-
2022
- 2022-08-08 CN CN202210943363.3A patent/CN115300458B/zh active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001000178A1 (fr) * | 1999-06-29 | 2001-01-04 | Takeda Chemical Industries, Ltd. | Comprimes se desintegrant rapidement dans la bouche |
| WO2005016310A1 (en) * | 2003-08-08 | 2005-02-24 | Elan Pharma International Ltd. | Novel metaxalone compositions |
| US20060140989A1 (en) * | 2004-12-22 | 2006-06-29 | Schering Corporation | Pharmaceutical formulations |
| CN104027566A (zh) * | 2014-06-06 | 2014-09-10 | 浙江天冉药物研究有限公司 | 健儿消食口服液及其制备工艺 |
| CN104758919A (zh) * | 2015-03-30 | 2015-07-08 | 锦州奥鸿药业有限责任公司 | 一种小牛血清去蛋白注射液及其制备方法 |
| CN107349351A (zh) * | 2017-08-07 | 2017-11-17 | 陕西必康制药集团控股有限公司 | 一种健儿消食口服液及其制备方法 |
| CN113730336A (zh) * | 2021-09-27 | 2021-12-03 | 浙江核力欣健药业有限公司 | 一种氯雷他定糖浆剂及其制备方法 |
| CN114588106A (zh) * | 2022-03-21 | 2022-06-07 | 哈尔滨圣泰生物制药有限公司 | 一种地氯雷他定口服溶液制剂及其制备生产工艺 |
Non-Patent Citations (1)
| Title |
|---|
| 王优杰: "模糊数学在中药口服液矫味中的应用", 中国中药杂志, vol. 34, pages 1 - 4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115300458B (zh) | 2023-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2093160C1 (ru) | Фармацевтическая композиция и способ воздействия на ретикулоэндотелиальную систему, лечения муковисцидоза и хронических болевых синдромов, сопровождающих заболевания опорно-двигательного аппарата и онкологические заболевания | |
| CN111346052B (zh) | 一种枸地氯雷他定口服液体制剂及其制备方法和应用 | |
| CN113730336A (zh) | 一种氯雷他定糖浆剂及其制备方法 | |
| CN108904476A (zh) | 一种盐酸氨溴索雾化吸入溶液剂及其制备方法 | |
| CN115300458A (zh) | 一种无糖地氯雷他定口服溶液及其制备方法 | |
| CN112451476A (zh) | 一种盐酸托莫西汀口服液及其制备方法 | |
| CN116440074A (zh) | 一种氯化钾口服制剂及其制备方法 | |
| CN110327293B (zh) | 一种右美沙芬愈创甘油醚口服液体制剂 | |
| CN115737552A (zh) | 一种盐酸氨溴索口服溶液及其制备方法 | |
| CN113143855B (zh) | 一种盐酸溴己新口服液及其制备方法 | |
| CN115475141A (zh) | 一种地氯雷他定口服溶液及其制备方法 | |
| CN114767677B (zh) | 一种氯雷他定组合物及其制备方法 | |
| CN112438949A (zh) | 一种含钙补充剂的盐酸托莫西汀口服液及其制备方法 | |
| CN118806761A (zh) | 一种氯雷他定口服制剂及其制备方法 | |
| Becker et al. | The glucose tolerance test and the response of intraocular pressure to topical corticosteroids | |
| CN112843062A (zh) | 一种含盐酸曲普利啶口服溶液及其制备方法 | |
| KR100547187B1 (ko) | 한국산 겨우살이 추출물을 이용한 항당뇨빵 제조방법과이로부터 얻어지는 항당뇨 활성을 갖는 당뇨빵 | |
| CN114246824B (zh) | 一种多奈哌齐口服凝胶及其制备方法 | |
| CN113413365B (zh) | 一种稳定的法维拉韦口服溶液制剂及其制备方法 | |
| CN118542836A (zh) | 一种硫酸特布他林口服溶液及其制备方法 | |
| CN116459211A (zh) | 一种盐酸奥洛他定口服溶液及制备方法 | |
| CN116785318A (zh) | 一种包含蒙脱石的药物组合物及其制备方法 | |
| US20230241097A1 (en) | Lozenge | |
| CN118304258A (zh) | 一种艾司西酞普兰口服液体制剂 | |
| Rizaeva et al. | DEVELOPMENT OF SYRUP TECHNOLOGY BASED ON ALTHEA EXTRACT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |